Evotec has received a milestone payment of €1.5 million from Boehringer Ingelheim from the companies’ research alliance. The milestone was for the transition of a pain molecule into preclinical development. Dr. Mario Polywka, chief operating officer of Evotec, commented, “This is the 18th milestone achieved as part of our alliance with Boehringer Ingelheim and represents an important transition of a compound into preclinical development. We are pleased the collaborative efforts of o...